Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial

Abstract

Key Points Rituximab prevents steroid-requiring chronic graft-vs-host disease when given after peripheral blood stem cell transplantation. Overall survival is improved with rituximab after allogeneic peripheral blood stem cell transplantation when compared with a control cohort.